A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
Zacks Investment Research on MSN
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
Intellia Therapeutics NTLA has made good progress with the advancement of its in vivo candidate, lonvo-z (or, NTLA-2002), ...
Bengaluru-based biotechnology startup CrisprBits Private Limited has raised USD 3 Million through founders, angels & family ...
CrisprBits has secured $3 Mn (INR 26.8 Cr) in a pre-Series A funding round led by Spectrum Impact and Rajendra Gogri's family ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback